1. Nutescu EA, Wittkowsky AK, Burnett A, Merli GJ, Ansell JE, Garcia DA. Delivery of optimized inpatient anticoagulation therapy: consensus statement from the anticoagulation forum.
Ann Pharmacother 47:2013;714–724.
2. Brodsky SV, Collins M, Park E, Rovin BH, Satoskar AA, Nadasdy G, Wu H, Bhatt U, Nadasdy T, Hebert LA. Warfarin therapy that results in an International Normalization Ratio above the therapeutic range is associated with accelerated progression of chronic kidney disease.
Nephron Clin Pract 115:2010;c142–146.
3. Brodsky SV, Nadasdy T, Rovin BH, Satoskar AA, Nadasdy GM, Wu HM, Bhatt UY, Hebert LA. Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate.
Kidney Int 80:2011;181–189.
4. Brodsky SV, Satoskar A, Chen J, Nadasdy G, Eagen JW, Hamirani M, Hebert L, Calomeni E, Nadasdy T. Acute kidney injury during warfarin therapy associated with obstructive tubular red blood cell casts: a report of 9 cases.
Am J Kidney Dis 54:2009;1121–1126.
5. An JN, Ahn SY, Yoon CH, Youn TJ, Han MK, Kim S, Chin HJ, Na KY, Chae DW. The occurrence of warfarin-related nephropathy and effects on renal and patient outcomes in korean patients.
PLoS One 8:2013;e57661.
6.
7. Ryan M, Ware K, Qamri Z, Satoskar A, Wu H, Nadasdy G, Rovin B, Hebert L, Nadasdy T, Brodsky SV. Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats.
Nephrol Dial Transplant 2013 Sep 5 Available at: 10.1093/ndt/gft380. (Epub) 2013 Sep 5.
8. Eknoyan G, Lameire N, Barsoum R, Eckardt KU, Levin A, Levin N, Locatelli F, MacLeod A, Vanholder R, Walker R, Wang H. The burden of kidney disease: improving global outcomes.
Kidney Int 66:2004;1310–1314.
9. Zhang QL, Koenig W, Raum E, Stegmaier C, Brenner H, Rothenbacher D. Epidemiology of chronic kidney disease: results from a population of older adults in Germany.
Prev Med 48:2009;122–127.
10. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review.
BMC Public Health 8:2008;117.
11. Ananthapanyasut W, Napan S, Rudolph EH, Harindhanavudhi T, Ayash H, Guglielmi KE, Lerma EV. Prevalence of atrial fibrillation and its predictors in nondialysis patients with chronic kidney disease.
Clin J Am Soc Nephrol 5:2010;173–181.
12. Kooiman J, van de Peppel WR, van der Meer FJ, Huisman MV. Incidence of chronic kidney disease in patients with atrial fibrillation and its relevance for prescribing new oral antithrombotic drugs.
J Thromb Haemost 9:2011;1652–1653.
13. Kleinow ME, Garwood CL, Clemente JL, Whittaker P. Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic.
J Manag Care Pharm 17:2011;523–530.
14. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, Arnett DK, Acton RT, Allon M. Kidney function influences warfarin responsiveness and hemorrhagic complications.
J Am Soc Nephrol 20:2009;912–921.
15. Chan KE, Lazarus JM, Thadhani R, Hakim RM. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation.
J Am Soc Nephrol 20:2009;2223–2233.
16. Kapoor KG, Bekaii-Saab T. Warfarin-induced allergic interstitial nephritis and leucocytoclastic vasculitis.
Intern Med J 38:2008;281–283.
17. Wysowski DK, Nourjah P, Swartz L. Bleeding complications with warfarin use: a prevalent adverse effect resulting in regulatory action.
Arch Intern Med 167:2007;1414–1419.
18. Abt AB, Carroll LE, Mohler JH. Thin basement membrane disease and acute renal failure secondary to gross hematuria and tubular necrosis.
Am J Kidney Dis 35:2000;533–536.
19. Kabir A, Nadasdy T, Nadasdy G, Hebert LA. An unusual cause of gross hematuria and transient ARF in an SLE patient with warfarin coagulopathy.
Am J Kidney Dis 43:2004;757–760.
20. Spetie DN, Nadasdy T, Nadasdy G, Agarwal G, Mauer M, Agarwal AK, Khabiri H, Nagaraja HN, Nahman NS Jr, Hartman JA, Hebert LA. Proposed pathogenesis of idiopathic loin pain-hematuria syndrome.
Am J Kidney Dis 47:2006;419–427.
21. Ozcan A, Ware K, Calomeni E, Nadasdy T, Forbes R, Satoskar AA, Nadasdy G, Rovin BH, Hebert LA, Brodsky SV. 5/6 nephrectomy as a validated rat model mimicking human warfarin-related nephropathy.
Am J Nephrol 35:2012;356–364.
22. Ware K, Brodsky P, Satoskar AA, Nadasdy T, Nadasdy G, Wu H, Rovin BH, Bhatt U, Von Visger J, Hebert LA, Brodsky SV. Warfarin-related nephropathy modeled by nephron reduction and excessive anticoagulation.
J Am Soc Nephrol 22:2011;1856–1862.
23. Lim AK, Campbell DA. Haematuria and acute kidney injury in elderly patients admitted to hospital with supratherapeutic warfarin anticoagulation.
Int Urol Nephrol 45:2013;561–570.
24. Berger R, Salhanick SD, Chase M, Ganetsky M. Hemorrhagic complications in emergency department patients who are receiving dabigatran compared with warfarin.
Ann Emerg Med 61:2013;475–479.
25. Nishio S, Tsuboi N, Kurashige M, Tanaka M, Ueda H, Yokoo T, Miyazaki Y, Utsunomiya Y, Hosoya T. A case of acute kidney injury during warfarin therapy.
Nihon Jinzo Gakkai Shi 55:2013;966–971.
26. August C, Atzeni A, Koster L, Heidenreich S, Lang D. Acute renal failure in IgA nephropathy: aggravation by gross hematuria due to anticoagulant treatment.
J Nephrol 15:2002;709–712.
27. Ware K, Qamri Z, Ozcan A, Satoskar AA, Nadasdy G, Rovin BH, Hebert LA, Nadasdy T, Brodsky SV. N-acetylcysteine ameliorates acute kidney injury but not glomerular hemorrhage in an animal model of warfarin-related nephropathy.
Am J Physiol Renal Physiol 304:2013;F1421–F1427.
28. Patel RP, Svistunenko DA, Darley-Usmar VM, Symons MC, Wilson MT. Redox cycling of human methaemoglobin by H
2O
2 yields persistent ferryl iron and protein based radicals.
Free Radic Res 25:1996;117–123.
29. Tracz MJ, Alam J, Nath KA. Physiology and pathophysiology of heme: implications for kidney disease.
J Am Soc Nephrol 18:2007;414–420.
30. Homsi E, Janino P, de Faria JB. Role of caspases on cell death, inflammation, and cell cycle in glycerol-induced acute renal failure.
Kidney Int 69:2006;1385–1392.
31. Tsiftsoglou AS, Tsamadou AI, Papadopoulou LC. Heme as key regulator of major mammalian cellular functions: molecular, cellular, and pharmacological aspects.
Pharmacol Ther 111:2006;327–345.
32. Coughlin SR. Protease-activated receptors in hemostasis, thrombosis and vascular biology.
J Thromb Haemost 3:2005;1800–1814.
33. Coughlin SR. Protease-activated receptors in vascular biology.
Thromb Haemost 86:2001;298–307.
34. Carlile-Klusacek M, Rizzo V. Endothelial cytoskeletal reorganization in response to PAR1 stimulation is mediated by membrane rafts but not caveolae.
Am J Physiol Heart Circ Physiol 293:2007;H366–H375.
35. Rondeau E, Vigneau C, Berrou J. Role of thrombin receptors in the kidney: lessons from PAR1 knock-out mice.
Nephrol Dial Transplant 16:2001;1529–1531.
36. Xu Y, Zacharias U, Peraldi MN, He CJ, Lu C, Sraer JD, Brass LF, Rondeau E. Constitutive expression and modulation of the functional thrombin receptor in the human kidney.
Am J Pathol 146:1995;101–110.
37. Favaloro EJ, Lippi G. Laboratory testing and/or monitoring of the new oral anticoagulants/antithrombotics: for and against?
Clin Chem Lab Med 49:2011;755–757.
38. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate.
Clin Pharmacokinet 47:2008;285–295.
39. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. Effects of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate, on thrombus formation and bleeding time in rats.
Thromb Haemost 98:2007;333–338.
40. Wienen W, Stassen JM, Priepke H, Ries UJ, Hauel N. In-vitro profile and ex-vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug, dabigatran etexilate.
Thromb Haemost 98:2007;155–162.
41. Ware KM, Vance JC, Muni N, Hebert LA, Satoskar AA, Nadasdy G, Ivanov I, Nadasdy T, Rovin BH, Brodsky SV. Oral warfarin and the thrombin inhibitor dabigatran increase blood pressure in rats: hidden danger of anticoagulants?
Am J Hypertens 2014 ,
10.1093/ajh/hpu129, 2014, in press.
42. Liu C, Wan J, Yang Q, Qi B, Peng W, Chen X. Effects of atorvastatin on warfarin-induced aortic medial calcification and systolic blood pressure in rats.
J Huazhong Univ Sci Technolog Med Sci 28:2008;535–538.
43. Krishnan S, Chawla N, Ezekowitz MD, Peixoto AJ. Warfarin therapy and systolic hypertension in men with atrial fibrillation.
Am J Hypertens 18:2005;1592–1599.
44. Dao HH, Essalihi R, Graillon JF, Lariviere R, De Champlain J, Moreau P. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension.
J Hypertens 20:2002;1597–1606.
45. Essalihi R, Dao HH, Yamaguchi N, Moreau P. A new model of isolated systolic hypertension induced by chronic warfarin and vitamin K1 treatment.
Am J Hypertens 16:2003;103–110.
46. Lim MA, Shafique S, See SY, Khan FN, Parikh CR, Peixoto AJ. Effects of warfarin on blood pressure in men with diabetes and hypertension—a longitudinal study.
J Clin Hypertens (Greenwich) 9:2007;256–258.